Nancy is the founding CEO of Syros and has an established track record of value creation in biotechnology. Prior to Syros, she was Chief Medical Officer at Millennium Pharmaceuticals, and previously, Vice President of Clinical Development at Biogen. Nancy has overseen the successful development of numerous medicines. Under Nancy’s leadership as Chief Medical Officer at Millenium, VELCADE became a mainstay of treatment for multiple myeloma.Nancy led development of Millenium’s clinical pipeline, including NINLARO for hematologic malignancies and ENTYVIO for inflammatory bowel disease. At Biogen, Nancy played a central role in developing AVONEX and TYSABRI for multiple sclerosis. Nancy started her career as an assistant professor at Harvard Medical School and neurology staff at Massachusetts General Hospital (MGH). She trained in neurology and internal medicine at MGH and graduated with a bachelor’s degree in biology from Princeton. She is currently a member of the board of directors of Seagen, the Biotechnology Innovation Organization (BIO) and the Damon Runyon Cancer Research Foundation.
.svg)
